| Age |
/decade |
574 |
1.05 (0.87, 1.27) |
0.63 |
465 |
1.20 (0.96, 1.48) |
0.10 |
109 |
0.60 (0.35, 1.02) |
0.059 |
| Months, Castration-sensitive Disease |
<12 mos vs ≥12 mos |
376 |
0.77 (0.49, 1.22) |
0.27 |
293 |
0.69 (0.41, 1.17) |
0.17 |
83 |
1.07 (0.40, 2.92) |
0.89 |
| Months, Disease-Metastases |
<36 mos vs ≥36 mos |
457 |
0.72 (0.49, 1.05) |
0.085 |
360 |
0.62 (0.40, 0.96) |
0.031 |
97 |
1.09 (0.46, 2.54) |
0.85 |
| Alk Phos |
Log-transformed |
433 |
1.10 (0.85, 1.41) |
0.49 |
355 |
1.18 (0.89, 1.56) |
0.26 |
78 |
0.74 (0.39, 1.37) |
0.33 |
| LDH |
Log-transformed |
255 |
0.72 (0.41, 1.26) |
0.24 |
192 |
0.91 (0.47, 1.75) |
0.78 |
63 |
0.44 (0.14, 1.42) |
0.17 |
| Neutrophils/Lymphocyte Ratio |
Log-transformed |
516 |
0.99 (0.76, 1.28) |
0.91 |
423 |
0.97 (0.73, 1.30) |
0.86 |
93 |
1.46 (0.68, 3.15) |
0.34 |
| Hemoglobin |
/unit |
540 |
1.17 (1.04, 1.32) |
0.008 |
438 |
1.16 (1.01, 1.32) |
0.034 |
102 |
1.15 (0.90, 1.46) |
0.27 |
| Baseline PSA |
Log-transformed |
572 |
1.02 (0.91, 1.14) |
0.75 |
464 |
1.03 (0.92, 1.17) |
0.60 |
108 |
1.00 (0.76, 1.32) |
0.99 |
| Charlson Score |
/unit≥10 vs <10 |
574 |
1.02 (0.94, 1.12)1.07 (0.76, 1.50) |
0.620.71 |
465 |
1.06 (0.96, 1.17)1.36 (0.93, 1.99) |
0.230.11 |
109 |
0.86 (0.67, 1.10)0.43 (0.19, 1.00) |
0.220.051 |
| Gleason Score |
≥8 vs <8 |
520 |
0.58 (0.40, 0.85) |
0.005 |
419 |
0.54 (0.35, 0.83) |
0.005 |
101 |
0.88 (0.39, 2.01) |
0.76 |
| Visceral Disease |
Yes vs No |
574 |
0.52 (0.27, 1.00) |
0.050 |
465 |
0.71 (0.33, 1.52) |
0.38 |
109 |
0.32 (0.09, 1.09) |
0.068 |
| Opiate Use |
Yes vs No |
571 |
0.92 (0.62, 1.37) |
0.69 |
463 |
0.93 (0.60, 1.44) |
0.74 |
108 |
1.04 (0.38, 2.82) |
0.94 |
| Treatment |
Enzalutamide vs Abiraterone |
574 |
0.95 (0.61, 1.47) |
0.81 |
|
- |
|
|
- |
|
| Concomitant Statins |
Yes vs No |
574 |
1.46 (1.02, 2.08) |
0.040 |
465 |
1.57 (1.05, 2.34) |
0.030 |
109 |
1.09 (0.48, 2.48) |
0.85 |
| Statin Type |
Atorvastatin vs Other |
194 |
0.76 (0.40, 1.42) |
0.38 |
154 |
0.77 (0.38, 1.58) |
0.48 |
40 |
0.59 (0.10, 3.59) |
0.56 |
| Dose of Statins |
/mg |
122 |
1.00 (0.98, 1.01) |
0.60 |
99 |
1.00 (0.98, 1.02) |
0.93 |
23 |
0.92 (0.84, 1.02) |
0.11 |
| Use of a hydrophilic statin |
Yes vs No |
173 |
1.06 (0.52, 2.16) |
0.88 |
150 |
1.18 (0.55, 2.55) |
0.67 |
23 |
0.76 (0.10, 5.94) |
0.80 |
| Multivariable Model |
| Age |
/decade |
379 |
0.98 (0.72, 1.33) |
0.87 |
312 |
1.04 (0.74, 1.47) |
0.83 |
67 |
0.76 (0.35, 1.64) |
0.48 |
| Alk Phos |
Log-transformed |
1.06 (0.78, 1.44) |
0.70 |
1.17 (0.84, 1.64) |
0.36 |
0.51 (0.20, 1.31) |
0.16 |
| Neutrophils/Lymphocyte Ratio |
Log-transformed |
1.16 (0.83, 1.62) |
0.37 |
1.15 (0.80, 1.65) |
0.46 |
1.93 (0.62, 6.01) |
0.26 |
| Hemoglobin |
/unit |
1.22 (1.04, 1.44) |
0.015 |
1.21 (1.01, 1.45) |
0.043 |
1.11 (0.76, 1.62) |
0.60 |
| Baseline PSA |
Log-transformed |
1.09 (0.93, 1.26) |
0.29 |
1.06 (0.90, 1.25) |
0.50 |
1.26 (0.78, 2.02) |
0.35 |
| Charlson Score |
≥10 vs <10 |
1.07 (0.65, 1.77) |
0.80 |
1.31 (0.74, 2.31) |
0.36 |
0.40 (0.11, 1.42) |
0.16 |
| Gleason Score |
≥8 vs <8 |
0.69 (0.43, 1.10) |
0.12 |
0.73 (0.43, 1.23) |
0.24 |
0.80 (0.26, 2.50) |
0.70 |
| Visceral Disease |
Yes vs No |
0.66 (0.28, 1.53) |
0.33 |
0.74 (0.26, 2.08) |
0.57 |
0.51 (0.11, 2.41) |
0.40 |
| Opiates |
Yes vs No |
0.97 (0.59, 1.57) |
0.89 |
1.09 (0.64, 1.87) |
0.75 |
0.77 (0.19, 3.20) |
0.72 |
| Treatment |
Enza vs Abi |
1.45 (0.81, 2.60) |
0.21 |
- |
- |
- |
- |
| Concomitant Statins |
Yes vs No |
1.63 (1.03, 2.60) |
0.039 |
1.80 (1.06, 3.06) |
0.029 |
1.02 (0.32, 3.21) |
0.97 |
